Navigation Links
Despite its Weak Pipeline, Schizophrenia Market May Benefit from Drugs Used in Similar Indications, Says GBI Research
Date:4/12/2016

LONDON, April 12, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Frontier Pharma: Schizophrenia and Associated Indications - states that although the schizophrenia market is replete with unmet needs and its pipeline is paltry, the overall level of innovation for schizophrenia-related indications - which comprise depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit - is far higher, and has the potential to provide some benefit to patients with schizophrenia.

The large population of schizophrenia patients in relation to its small pipeline of 134 products is indicative of a low level of investment in Research and Development (R&D), most likely due to a poor understanding of the underlying disease mechanisms. This acts as a strong barrier to the development of effective pharmaceutical products.

Managing Analyst Dominic Trewartha explains: "While current treatments offer some relief from symptoms such as hallucinations, they have not proven as effective for cognitive dysfunction and symptoms such as the inability to feel pleasure, and there are no disease-modifying drugs currently available. A number of combinations, such as the addition of adjuvant agents to antipsychotic medication, have been trialed, but they have had little impact."

GBI Research states that there are 360 products in the pipeline for conditions associated with schizophrenia, 60 of which are first-in-class, equating to 21% of products with a disclosed molecular target. Overall, while the proportion of first-in-class products is still low, there are more in the pipeline for schizophrenia-related indications, particularly depressions and cognitive deficit, than there are for schizophrenia itself, and these act across a far wider range of molecular targets.

Trewartha continues: "The range of innovation is relatively diverse in the pipelines for schizophrenia and related indications, with products acting on numerous novel molecular targets, including D-Amino Acid Oxidase, glutamate carboxypeptidase 2, and a number of probable G protein-coupled receptors.

"It is likely that small molecules will remain clinically and commercially the most successful molecule types across many therapy areas and indications, being particularly relevant in the central nervous system (CNS) and schizophrenia, with only limited prospects that new product approvals could change the landscape.

"Despite industry-wide trends towards a diversification in therapeutic molecule types, it is unlikely that this will be translated in CNS disorders and schizophrenia, due to the challenges of crossing the blood-brain barrier with larger and more complex molecular types."

Sample pages of GBI Research's report Frontier Pharma: Schizophrenia and Associated Indications are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:

+44(0)161-359-5817 

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter



'/>"/>
SOURCE GBI Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline
2. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
3. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
4. Despite A Difficult Competitive Environment, Opportunities Can Still Be Found In The Growing US Trauma Fixation Device Market
5. Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
6. ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
7. Power Morcellator Critic Vows to Carry On Despite Threat of Legal Action, Bernstein Liebhard LLP Reports
8. Despite Its Limited Size, Chiles Pharmaceutical Market Offers Growing Opportunity for Drug Industry
9. Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
10. Asia-Pacific Rheumatoid Arthritis Therapeutics Markets 2015-2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
11. Despite Push for Transparent Medical Records, 53% of Consumers Cant Access Electronic Health Data, HealthMine Survey Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2018)... ... October 17, 2018 , ... ... published a new technique documenting the use of placental based growth factors for ... According to Dr. Holtzclaw, “At our DIA Dental Implant Center locations in Austin ...
(Date:10/17/2018)... , ... October 17, 2018 , ... ... methods of connection to your video conferencing platform and intuitive adjustments maximize the ... button for selecting the desired auscultation area on the body, which automatically adjusts ...
(Date:10/16/2018)... ... October 16, 2018 , ... Citrus Valley Health Partners ... an exciting and inclusive forum on the health care ecosystem of the San Gabriel ... designed to foster evidence-based dialogues and actionable solutions aimed at transforming the way health ...
Breaking Medicine Technology:
(Date:10/20/2018)... (PRWEB) , ... October 20, 2018 , ... CBD Hacker, ... oils for 2018. The list is the result of a comparative analysis of the ... have to sort through a ton of different information to choose the right product,” ...
(Date:10/18/2018)... (PRWEB) , ... October 18, 2018 , ... ... his expertise in aesthetic and reconstructive surgery, recently joined Dr. Robert Cohen ( ... , "I'm extremely honored and excited to have a plastic surgeon of Dr. ...
(Date:10/17/2018)... ... October 17, 2018 , ... The Jacobs & Cushman San Diego Food Bank’s ... at a meeting of its Board of Directors. , California Association of Food ... California. CAFB provides its member food banks with a range of support services, direct ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... business loans, equipment leasing, and franchise financing , is now recognized by ... States. Balboa Capital will structure and deliver custom-tailored financing programs to Massage Envy ...
(Date:10/16/2018)... ... , ... dicentra Global Certifications, an affiliate of dicentra Cannabis Consulting, has announced ... the first G7 country in the world to formally legalize the recreational production and ... the production and use of cannabis edibles. , More than one in four Canadians ...
Breaking Medicine News(10 mins):